Comparison of Efficacy of Two Mandibular Advancement Devices (MADs) During Sleep
- Conditions
- Apnea Syndrome
- Interventions
- Device: custom-made adjustable mandibular advancement device
- Registration Number
- NCT04474756
- Lead Sponsor
- University Hospital, Grenoble
- Brief Summary
Mandibular Advancement Devices (MADs) are now a reliable alternative to continuous positive airway pressure (CPAP) treatments for Obstructive Sleep Apnea (OSA) . Despite good tolerance and efficacy, there are still barriers limiting the widespread use of MAD and its acceptance in OSA routine clinical practice. Various MAD designs currently exist and constantly emerge on the market without clear evidence regarding the best technical choice and the cost-effectiveness compromise. Although these MAD has been tested in term of efficacy, no study has tested the difference between MADs in term of efficacy, tolerance and patient satisfaction. The aim of this clinical trial is to compare the effectiveness of two MADs - custom-made titratable MAD (NarvalTM) and customizable titratable MAD (TALITM), over a 3-month period, in patients with obstructive sleep apnea (OSA).
- Detailed Description
Obstructive Sleep Apnea (OSA) is characterized by repetitive episodes of partial or complete pharyngeal obstruction during sleep. OSA is one of the most frequent chronic diseases with both social and multi-organ consequences making it an economic burden for society. OSA durably impairs the quality of life of patients and their entourage and is associated with co-morbidities including hypertension, arrhythmias, stroke, coronary heart disease and metabolic dysfunction.
Continuous positive airway pressure (CPAP), the first line therapy for OSA, requires high adherence to be effective in terms of symptom improvement and reduction of the burden of co-morbidities. For one third of patients, such adherence is difficult to achieve in the long term and mandibular advancement devices (MAD) have emerged as the leading alternative to CPAP. So, MADs are now a reliable alternative to CPAP treatments, which position these in numerous patients as a first therapy. Moreover, mild to moderate symptomatic patients who refuse to be diagnosed are now referring to sleep centers in order to be treated. MAD and CPAP are similarly effective on symptoms, quality of life and in attaining reductions in blood pressure and cardiovascular morbidity. Although CPAP has a greater effect on Apnea + hypopnea index (AHI) reduction, adherence is better with MAD explaining the comparable mean disease alleviation achieved by the two treatment modalities.
Despite good tolerance and efficacy, there are still barriers limiting the widespread use of MAD and its acceptance in OSA routine clinical practice. Various different MAD designs currently exist and constantly emerge on the market without clear evidence regarding the best technical choice and the cost-effectiveness compromise. Titratable two-piece custom-made MADs are the gold standard in clinical guidelines and several brands are now on the market. Although these MAD has been tested in term of efficacy, no study has tested the difference between MADs in term of efficacy, tolerance and patient satisfaction. Such a paradigm merits being tested in a randomized controlled trial. The SONAR study is a multicenter, parallel-group randomized controlled trial to determine if the titratable MAD NARVAL TM is superior to the titratable MAD TALITM in OSA patients eligible for MAD. The primary outcome will be the treatment response at 3 months assessed by the difference of delta AHI at baseline and follow-up measured by polysomnography and secondary outcomes focus at global efficacy, tolerance and patient satisfaction.
To our knowledge it will be the first study comparing two titrable MADs.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 90
-
Signed written informed consent before participation
-
Age ≥18 years
-
Moderate to severe OSA defined by:
- AHI ≥30 or,
- 15≤ AHI <30, but associated with excessive daytime sleepiness or,
- 15≤ AHI <30, with at least two of the following criteria not explained by other factors: severe and daily snoring, choking or suffocating sensation during sleep, non-restorative sleep, daytime fatigue, difficulty concentrating, nocturia (more than one urination per night).
-
Naïve from any mandibular advancement device
-
Patient affiliated to a social security/health insurance system
-
One or more of the following contra-indications:
- dental problems (tooth failure, poor distribution or insufficient dental retention)
- periodontal problems: active periodontitis not stabilized. Presence of periodontal pockets, advanced bone loss, significant tooth mobility, insufficient dental plaque control.
- temporomandibular joint disorder (TJD)
- maximum mandibular propulsion distance limited (< 6 mm)
-
More than 20% of central apnea and hypopnea
-
Severe psychiatric or neuromuscular disorder
-
Body Mass Index (BMI) > 30 kg/m2
-
Current orthodontic treatment or planned during the study
-
Pregnant women based on clinical exam and medical questioning.
-
Subject in exclusion period of another interventional study
-
Subject under administrative or judicial control
-
Subject unable to understand, follow objectives or methods due to cognition or language problems
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Mandibular Advancement Devices Narval™ custom-made adjustable mandibular advancement device The tested device Narval™ will be a custom-made adjustable bi-block mandibular advancement device, that is made with semi-rigid plastic materials (bio-compatible polymer) and customized using a high-precision computer-aided design (CAD)/computer-aided manufacturing (CAM) ) (ResMed, Narval CC™). The Mandibular Advancement Devices will be gradually adjusted to provide mandibular advancement over a 15-mm range. Each Mandibular Advancement Device will be fitted by a dental specialist with an initial advancement of about 60 % of maximal jaw protrusion. During titration, mandibular advancement will be adjusted at the discretion of the dental specialist. Mandibular Advancement Devices TALI ™ custom-made adjustable mandibular advancement device The control device TALI ™ is a mandibular advancement orthesis, customized and manufactured by the "laboratoire TALI", of the bi-bloc type consisting of rigid gutters thermo-formed on the plaster dental arches and articulated by two links of variable size allowing to adjust the advance in steps of 1 millimeter. This orthesis is manufactured on molding from bio-compatible plastic materials. The different sizes of rods proposed allow mandibular advances of 4 mm to 16 mm. Two clinical studies evaluated the effectiveness of the AMC / AMO orthosis (initial version of the TALI orthesis, with non-curved links) in patients with OSA. They have already demonstrated the effectiveness of the TALI orthesis by decreasing AHI and drowsiness; most patients preferred to use the orthesis (76.4% vs. 9.1%)11.
- Primary Outcome Measures
Name Time Method Comparison of efficacy of two Mandibular Advancement Devices: NarvalTM and TALITM at the end of the 3-month period The difference of effectiveness between Mandibular Advancement Devices will be assessed using the difference of delta AHI, measured by Polysomnography, between the visit 2 (M3) and the Polysomnography before Mandibular Advancement Devices installation.
- Secondary Outcome Measures
Name Time Method To compare the sleep quality after 3 months of treatment with mandibular advancement device RDI, total sleep time, TST, PST, Sleep latency, WASO, Sleep efficiency, Time in stage I, II, SWS and REM sleep respectively, Total micro-arousals, respiratory micro-arousals and PLM micro-arousals, assessed by Polysomnography.
To compare the efficacy of titration with each Mandibular Advancement Devices between the oral appliance delivery and the end of the titration period at 3 months Delay of titration period, number of additional titration visits required
To compare the number of patients appropriately treated by Mandibular Advancement Devices between the two devices after 3 months of treatment with mandibular advancement device Rate of complete response (AHI\<10) or partial response (AHI\<15) of treatment:
The percentage of patients with AHI \<15, or ≥ 50% reduction in AHI from baseline (D0) to D90 (3 months), associated with a subjective (patient reported) compliance ≥ 5 nights/week and 5 hours/night. AHI assessed by polysomnographyTo compare the effect of obstructive sleep apnea on patient's quality of life after 3 months of treatment with each Mandibular Advancement Device by Quebec Quality of life questionnaire
To compare patient satisfaction after 3 months of treatment with mandibular advancement device using the Questionnaire VSQ-VF
To compare the tolerance in the 2 arms after 3 months of treatment Rate of side effects, jaw discomfort (visual analogic scale) scale), mean number of hours by night wearing the mandibular device (patient diary), therapy withdrawals
To compare the mandible behavior (mandibular movement (MM)) during sleep) with each Mandibular Advancement Device after 1 month and 3 month of treatment with each Mandibular Advancement Device Mandibular movement, RDI and time spent in respiratory effort, assessed by home-based recording (by Class IIA polygraphic device: Sunrise® Solution with mandibular movement recording), and mandibular movement recording by Jaw-ac technology, added to the classical procedure (Polysomnography)
To compare the evolution of obstructive sleep apnea associated subjective daytime sleepiness with each Mandibular Advancement Device after 3 months of treatment with each Mandibular Advancement Device by Epworth sleepiness score
To compare subjective snoring perception by the patient's environment after 3 months of treatment with each Mandibular Advancement Device by subjective snoring (visual analogic scale-VAS)
Trial Locations
- Locations (1)
Grenoble University Hospital
🇫🇷Grenoble, Isère, France